Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angiocentric lymphoma16.17.04.002; 01.11.04.0020.001410%Not Available
Anorectal disorder07.03.01.0010.000627%Not Available
Aortic stenosis24.04.01.0010.000313%Not Available
Aphasia17.02.03.001; 19.21.01.001--
Aphthous ulcer07.05.06.0020.001097%Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.0010.001723%Not Available
Aplastic anaemia01.03.03.0020.001097%Not Available
Apnoea22.02.01.0010.000313%
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.0010.000313%Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.0010.014193%
Arthritis15.01.01.0010.001473%
Arthropathy15.01.01.0030.001159%Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.002820%
Asthenia08.01.01.0010.006579%Not Available
Atelectasis22.01.02.0010.000470%
Atrial flutter02.03.03.003--
Autoimmune hepatitis09.01.07.019; 10.04.09.0010.000313%Not Available
B-cell lymphoma16.28.01.001; 01.15.01.0010.001723%Not Available
Back pain15.03.04.005--
Basal cell carcinoma23.08.02.001; 16.03.02.0010.002412%Not Available
Bile duct stone09.02.02.003--Not Available
Blindness unilateral06.02.10.007; 17.17.01.0160.000313%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin increased13.03.04.018--
Blood pressure fluctuation24.06.01.0020.000627%Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.0040.000313%Not Available
Bowen's disease23.08.02.004; 16.03.02.0040.000313%Not Available
Breast cyst21.05.01.006; 16.14.01.004--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene